Syreach notes actinium

NEW YORK, Jan. 13, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced the research collaboration with Astellas Pharma Inc. (TSE:4503) ("Astellas") to develop novel targeted radiotherapies using its Antibody Warhead Enabling (AWE) technology platform. Under this agreement, Actinium will utilize its AWE Platform technology to develop and characterize selected Astellas targeting agents labeled with the potent alpha-emitting radioisotope Actinium-225 (Ac-225). This collaboration is a component of Astellas' internal initiative to develop theranostics as part of its Rx+ ® business (For more information, please visit are excited to execute on this research collaboration with Astellas, a global leader at the forefront of healthcare innovation," stated Dr. Dale Ludwig, Chief Scientific and Technology Officer of Actinium. "Targeted radiotherapy has a highly differentiated mechanism of action with the potential to address multiple disease indications and therefore has been an area of significant exploration and investment of late. Through our AWE technology platform, we are able to bring our significant know-how in working with Actinium-225, as well as our robust clinical experience with targeted radiotherapies and supply chain to bear in this collaboration. With our enhanced laboratory capabilities and the expertise of our R&D team, we are well positioned to execute on this collaboration with Astellas as well as our own R&D strategy, to complement our Iomab-B and Actimab-A clinical programs."The intellectual property encompassing Actinium's AWE technology platform covers its gold standard linker technology, methods of ARC manufacture in addition to methods of use for ARCs in multiple diseases, including indication, dose and scheduling, radionuclide warhead, and therapeutic combinations. Actinium's AWE technology patent portfolio includes 30 patent families comprised of over 135 issued or pending global patent applications, of which 10 are issued and 24 pending in the United States.Sandesh Seth, Chairman and Chief Executive Officer of Actinium, added, "Through

Our development efforts, Actinium has established itself as a leader in the field of Actinium-225 based targeted radiotherapies. We have amassed the most experience treating patients with Actinium-225 via our CD33 program's several Actimab-A trials and have gained important insights in developing targeted radiotherapies through the execution of the Actimab-A and also SIERRA Phase 3 pivotal trial for our lead asset, Iomab-B. This expertise and experience with radiopharmaceuticals has been invaluable to us and we believe will also be to Astellas in this collaboration. As Iomab-B and Actimab-A advance in the clinic with multiple clinical milestones upcoming from each of our trials, we look forward to executing this collaboration and furthering the field of targeted radiotherapy with Astellas." About Our Antibody Warhead Enabling Platform TechnologyThe Antibody Warhead Enabling (AWE) Program has at its centerpiece the AWE Platform Technology. The Company's proprietary AWE Platform Technology is supported by intellectual property and know-how that enables the creation of Actinium-225 (Ac-225) Radio-Conjugates (ARCs) wherein a biomolecular targeting agent is stably labeled with the powerful Ac-225 payload to enhance targeted cell killing. The AWE Platform is protected by intellectual property covering the use of the "gold standard" chelator DOTA, and any conceivable derivative thereof. Additionally, Actinium holds intellectual property protection covering methods of chelation or labeling of the targeting agent with Ac-225, including newer next-generation methodologies for chelation of Ac-225.The AWE Program is structured to provide the opportunity for partners or collaborators to derive maximum value from a collaboration by leveraging Actinium's extensive technical know-how, access to its ARC drug development infrastructure and to its underlying AWE Platform Technology. The AWE Program provides a partner or collaborator with access to Actinium's knowledge bank and infrastructure allowing collaborators to benefit from accelerated development timelines for its ARCs.To learn more about the AWE Technology Platform or

Actinium Pharmaceuticals ( (ATNM) ) has released its Q3 earnings. Here is a breakdown of the information Actinium Pharmaceuticals presented to its investors.Actinium Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the development of targeted radiotherapies and Antibody Radiation Conjugates (ARCs) aimed at improving treatment outcomes for patients with high unmet medical needs, particularly in the field of hematology and oncology. In its latest earnings report for the quarter ending September 30, 2024, Actinium Pharmaceuticals highlighted the continuation of its research and development activities, despite reporting no revenue for the period. The company is focused on advancing its pipeline, which includes lead product candidates Iomab-B and Actimab-A, aimed at treating relapsed or refractory acute myeloid leukemia (AML).The financial metrics reveal a net loss of $11.6 million for the three months ended September 30, 2024, a reduction from the $13.3 million loss reported for the same period in 2023. This improvement in financial performance is attributed to a decrease in research and development expenses, which dropped to $9.8 million from $11.6 million in the previous year, and a reduction in general and administrative expenses. The company also raised $29.3 million through the sale of common stock, enhancing its cash position to $78.7 million.Actinium Pharmaceuticals remains committed to its strategic focus on developing radiotherapeutics for relapsed or refractory cancer patients. The management’s outlook is centered on advancing clinical trials for Iomab-B and Actimab-A, while also exploring new applications for its ARC platform in solid tumor indications. With an active research and development pipeline, the company aims to bring novel treatment options to market, addressing areas with significant unmet medical needs.Trending ArticlesClass Action Lawsuit Against Metagenomi Inc. (NASDAQ:MGX) DOJ to Push Alphabet’s Google to Sell Chrome Browser in Antitrust Move Super Micro Stock Soars 40% on Hiring New Auditor and Averting Delisting